NABRIVA THERAPEUTICS

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch NBRVF and buy or sell other stocks, ETFs, and their options commission-free!

About NBRVF

Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the commercialization and development of novel anti-infective agents to treat infections. The company was founded in October 2005 and is headquartered in Dublin, Ireland. 

CEO
H. Michael Hogan
CEOH. Michael Hogan
Employees
39
Employees39
Headquarters
Dublin, Dublin
HeadquartersDublin, Dublin
Founded
2017
Founded2017
Employees
39
Employees39

NBRVF Key Statistics

Market cap
323.08
Market cap323.08
Price-Earnings ratio
Price-Earnings ratio
Dividend yield
Dividend yield
Average volume
Average volume
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$0.0002
52 Week high$0.0002
52 Week low
$0.00
52 Week low$0.00

Stock Snapshot

As of today, NABRIVA THERAPEUTICS(NBRVF) shares are valued at $0.00. The company's market cap stands at 323.08.

NABRIVA THERAPEUTICS(NBRVF) stock opened on 2026-07-25 at —. The price climbed to — and dipped to —.

The NABRIVA THERAPEUTICS(NBRVF)'s current trading volume is 0.

In the last year, NABRIVA THERAPEUTICS(NBRVF) shares hit a 52-week high of $0.00 and a 52-week low of $0.00.

In the last year, NABRIVA THERAPEUTICS(NBRVF) shares hit a 52-week high of $0.00 and a 52-week low of $0.00.

People also own

Based on the portfolios of people who own NBRVF. This list is generated using Robinhood data, and it’s not a recommendation.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.